Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

BMS to pay Eisai $650 million for antibody-drug conjugate

by Ryan Cross
June 26, 2021 | A version of this story appeared in Volume 99, Issue 24

 

Bristol Myers Squibb will pay Eisai $650 million to jointly develop the Tokyo-based firm’s first antibody-drug conjugate (ADC) for cancer. Eisai also could earn up to $2.45 billion in milestone payments. The antibody targets cancers expressing folate receptor α. It then delivers a small-molecule payload called eribulin, Eisai’s simplified and synthetic version of halichondrin B, a toxic microtubule dynamics inhibitor derived from sea sponges. The therapy is in Phase 1 studies as a possible treatment for endometrial, ovarian, lung, and breast cancers.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.